Martin Shkreli (left), former CEO of Turing Pharmaceuticals, leaves a February 2016 House Oversight and Government Reform Committee on "methods and reasoning behind recent drug price increases," after invoking his Fifth Amendment right against self-incrimination. Turing had raised the price of Daraprim, a drug used by AIDS and cancer patients, from $13.50 to $750 a pill. (Tom Williams/CQ Roll Call)
Martin Shkreli (left), former CEO of Turing Pharmaceuticals, leaves a February 2016 House Oversight and Government Reform Committee on “methods and reasoning behind recent drug price increases,” after invoking his Fifth Amendment right against self-incrimination. Turing had raised the price of Daraprim, a drug used by AIDS and cancer patients, from $13.50 to $750 a pill. (Tom Williams/CQ Roll Call)